Condition
Low Back Pain: Options and What the Evidence Actually Shows
Most low back pain is nonspecific and improves with time and movement. Regenerative marketing should not outrun that reality.
Anatomy and clinical context
Nonspecific low back pain is extremely common. Red flags (infection, fracture, cauda equina, cancer signs) change the pathway immediately.
For typical mechanical pain, guidelines prioritize staying active and avoiding unnecessary imaging early.
Illustration of the lumbar spine
The standard-of-care ladder
Conservative care first, then injections, then surgery when indicated. Cell therapy belongs in that conversation — not above it.
- Step 1
Conservative care
Stay active, PT, self-management, and short-course meds when needed.
- Step 2
Injections
Injections for radicular or facet-mediated pain after appropriate workup; regenerative options only in informed specialty settings.
- Step 3
Surgery
Surgery for clear structural indications — not for nonspecific pain alone.
Where cell therapy fits
Cell therapy is not first-line for nonspecific low back pain. Use this page to understand the field — then decide with a physician whether any interventional path fits.
- Most episodes improve without procedures.
- Regenerative injectates are not guideline first-line for nonspecific LBP.
- Banking is a separate decision about future dose, not a back-pain cure.
Selected citations
MILES
Mautner et al. · Nature Medicine (2023)
n=440 knee OA trial: BMAC, umbilical tissue, and SVF vs corticosteroid — none beat steroid at one year; none moved MRI scores.
Why dose and donor age change the picture
The trials that disappoint used unexpanded cells from older donors.
The ones that work used expanded cells at therapeutic dose. Dose is the variable — and dose is what expansion buys you. Potency is what your age buys you.
- 1
Cells work at dose.
A same-day draw yields a small, uncounted, unexpanded fraction. Expansion turns one draw into many doses.
- 2
Potency is age-dependent, and it is a one-way door.
Your MSCs at 35 are not your MSCs at 55. Banking is the only mechanism that makes 35-year-old cells available to a 55-year-old.
- 3
Expansion is what makes the bank a supply, not a souvenir.
Bank once, expand repeatedly, across a treatment course rather than a single shot. Culture expansion for Forever Labs members is rolling out — starting with selected states as our Florida cGMP lab comes online.
- 4
The provider decides what happens next.
We supply cells; they practice medicine. Forever Labs does not treat conditions — your physician owns the clinical relationship.
Two next steps — equal weight
Forever Labs does not treat conditions. Your physician owns the clinical relationship. We bank cells and, as expansion rolls out, help make dose possible.